BUND FINANCE › Stocks › RMD
ResMed Inc. (RMD)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 19, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +1.60% above its 50-day average.
- It is +5.92% above its 200-day average (long-term uptrend).
- It sits at 58% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | US$3.6B | US$4.2B | US$4.7B | US$5.1B | US$5.7B |
| Net income | US$779.4M | US$897.6M | US$1.0B | US$1.4B | US$1.5B |
| EPS (diluted) | 5.30 | 6.09 | 6.92 | 9.51 | 10.40 |
| Gross margin | 56.6% | 55.8% | 56.7% | 59.4% | 61.1% |
| Operating margin | 28.0% | 26.8% | 28.2% | 32.8% | 33.8% |
| Net margin | 21.8% | 21.3% | 21.8% | 27.2% | 26.9% |
| Free cash flow | US$195.1M | US$559.3M | US$1.3B | US$1.7B | US$1.6B |
| Total debt | US$917.6M | US$1.6B | US$873.9M | US$851.8M | US$825.9M |
| Cash | US$273.7M | US$227.9M | US$238.4M | US$1.2B | US$1.5B |
Compound annual growth: revenue 12.1% · net income 18.2% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 21.6x | 29.5x | 26.4x |
| EV / EBITDA | 14.7x | 20.4x | 16.3x |
| Operating margin | 33.1% | — | 3.6% |
| Net margin | 27.8% | — | -0.0% |
| Debt / equity | 0.38 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About ResMed Inc.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable sof…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice